Although five HDAC inhibitors have been approved and more than 20 new HDAC inhibitors are currently under preclinical and clinical investigations against various cancer, none of these HDAC inhibitors are specifically developed for the treatment of GBM; therefore, the development of new HDAC inhibitors for GBM is an ongoing opportunity and challenge. This evidence concerns the gene HDAC9 and glioblastoma.